Keywords: myotrophin, dossier, withdrawn, eu, cephalon, chiron, application
Myotrophin Dossier Withdrawn In EU
Article | 17 September 1998
Cephalon and Chiron have withdrawn their application to marketMyotrophin (mecasermin) for amyotrophic lateral sclerosis in the European Union. The move ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
